Prevalence of Markers of Heart Failure in Patients with Atrial Fibrillation and the Effects of Ximelagatran Compared to Warfarin on the Incidence of Morbid and Fatal Events: A Report from the SPORTIF III and V Trials

Abstract

Patients with markers of heart failure, even if the diagnosis is not well established, are at increased risk of thromboembolic events and might be targeted for more effective antithrombotic therapy. This might include patients in sinus rhythm as well as AF.